Such approved drugs include inhibitors of TNF-α (e.g., etanercept and adalimumab), IL-6 (e.g., tocilizumab), and IL-1β (e.g., canakinumab) signaling for immune diseases such as rheumatoid arthritis and Crohn’s disease [41]. The gene discussed is TNF; the disease is immune system disorder.